Glenmark Generics Ltd, a subsidiary of Glenmark Pharmaceuticals Ltd, has confirmed that Smithkline Beecham Corporation (d/b/a) Glaxosmithkline (GSK) filed a patent infringement lawsuit on their US subsidiary, Glenmark Generics Inc, USA (Glenmark) in the US District Court for the District of Delaware in connection with the Abbreviated New Drug Application (ANDA) filing for Atovaquone and Proguanil hydrochloride 250mg/ 100mg tablets.

Also Read   Related Stories News Now - Maruti, Asian Paints at life-time high - NEWSALERT: GlaxoSmithkline Consumer Healthcare posts 20% rise in Q1 profit - Lupin, Matrix face antitrust probe in EU - GSK Consumer slips after posting new high - Dr Reddy's signs strategic pact with GSK - GlaxoSmithKline to launch up to 12 products this year   Also Read   Related Stories News Now - Sensex makes remarkable recovery, regains 17K - Bharati to go by Sebi norms on Great Offshore offer - Galleon exits Edelweiss; sells 7% stake for Rs 255.54 cr - Suzlon Energy's three promoters pledge 2.8 cr shares - Draw export strategy of $300 bn: Assocham to govt More

GSK currently markets their product as Malarone(R) in the United States and is indicated for the prevention and treatment of malaria. Total US sales as reported by IMS Health for the 12 month period ending June 2009 were approximately $53 million.  

Glenmark believes it is the sole first to file applicant on this product. Glenmark had earlier filed its ANDA containing a paragraph IV certification for its generic version of atovaquone and proguanil hydrochloride tablets with the US Food & Drug Administration (FDA), and following receipt of the notice from the FDA that Glenmark’s ANDA had been accepted for filing, notified the New Drug Application (NDA) holder and patent owner.
  
Smithkline Beecham Corporation’s lawsuit is part of the patent challenge process under the Hatch Waxman Act. Based on the information published by the FDA, Glenmark believes it may be the first applicant to have filed an ANDA for this product with a paragraph IV certification. In the event that Glenmark successfully challenges the patent, Glenmark will he entitled to a 180-day exclusively period.

Glenmark’s current portfolio consists of over 40 products authorised for distribution in the US marketplace. The company has 45 ANDA’s pending for approval with the US FDA.

With this filing, Glenmark has four sole first-to-file products currently under litigation under the Hatch-Waxman Act. The other three products are Zetia(R) (Ezetimibe), Tarka ® (Trandolapril + Verapamil) and Cutivate ® (Flutleasone lotion) - Pending successful patent challenges, Glenmark will be entitled to sole marketing exclusively for the 180-day period. 

Other Stories      - Sensex makes remarkable recovery, regains 17K - Bharati to go by Sebi norms on Great Offshore offer - Galleon exits Edelweiss; sells 7% stake for Rs 255.54 cr - Suzlon Energy's three promoters pledge 2.8 cr shares - Draw export strategy of $300 bn: Assocham to govt More

Tags : glenmark pharmaceuticals ltd | glenmark generics ltd | Smithkline Beecham Corporation | Glaxosmithkline   Read Business news in  Advertisements   Get financial advisory and solutions for your projects   Holidays starting at a delightful EMI of Rs 3481   Switch on and say hello to Monday morning !   Your dream home can now be a reality.   Visit Fortis for a preventive health check-up & get a 20% discount.   Follow the ups and downs of your investments. Try our new Portfolio Tracker   Kolkata Dock \ Freight contract for the British Gurkhas Nepal   Find how Midsize Businesses use ERP to gain competitive advantage   Trading in Forex is now as easy as 1-2-3   Discover an economical and cost effective way to market your products and services   Giftwithlove.com: Same day delivery of Flowers and Cakes to India   Download the E-book on the Future of Business Intelligence   Learn Best Practices for improving customer satisfaction   Know your customers better... download the free e-book on CRM